CytoDyn Inc. (CYDY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Vancouver, WA, United States. The current CEO is Jacob Lalezari.
CYDY has IPO date of 2006-12-13, 9 full-time employees, listed on the Other OTC, a market capitalization of $457.85M.
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
